Biofrontera Inc. Moves Forward with Ameluz® Phase 3 Study Insights
Biofrontera Inc. Progresses in Phase 3 Clinical Study of Ameluz®
WOBURN, Mass. — Biofrontera Inc. (Nasdaq: BFRI), a leading biopharmaceutical company focusing on innovative photodynamic therapy (PDT), has reached a significant milestone by completing the active treatment phase of its Phase 3 clinical trial for Ameluz® (10% 5-aminolevulinic acid hydrochloride gel) aimed at treating mild to moderate actinic keratoses (AKs) on the extremities, neck, and trunk. This study added a notable chapter in the company’s journey, now moving into the 12-month follow-up phase.
The Importance of Actinic Keratoses Treatment
Actinic keratosis is a prevalent precancerous skin condition affecting various sun-exposed regions, impacting around 58 million adults in the U.S. Importantly, untreated AK lesions can progress to cutaneous squamous cell carcinoma, with a concerning majority arising from AKs. As such, expanding treatment options for AKs beyond the facial and scalp areas is a crucial need in dermatology.
Details of the Phase 3 Study
The Phase 3 study was meticulously designed as a multicenter, randomized, double-blind trial to rigorously evaluate the safety and effectiveness of Ameluz® PDT compared to a vehicle gel. Participants received either one to three tubes of Ameluz® or the vehicle gel applied to treatment areas of varying sizes, followed by PDT utilizing a RhodoLED® or BF-RhodoLED® XL lamp. This approach aimed to deliver targeted treatment while closely monitoring the required follow-ups.
Future Prospects for Biofrontera
CEO and Chairman Dr. Hermann Luebbert expressed enthusiasm about reaching this milestone in their clinical progression, stating that the recent FDA approval for the use of up to three tubes of Ameluz® per treatment is paving the way for a broader market potential. This significant step reflects Biofrontera’s strategic initiative to establish itself at the forefront of PDT.
Expert Insights on Treatment Expansion
Clinical investigator Dr. Nathalie Zeitouni commented on the positive impact this treatment could have for dermatologists and patients alike. The potential to treat AK lesions extensively on the trunk and extremities with Ameluz® PDT offers a much-needed development in patient care. With limited current treatment options, this advancement could significantly enhance treatment outcomes.
Projected Timeline for the Study
As the 12-month follow-up phase unfolds, it is expected to conclude in the second quarter of the following year. Upon obtaining favorable results, Biofrontera plans to submit a supplemental New Drug Application (sNDA) to the FDA, highlighting its commitment to addressing this pressing health concern.
Understanding Actinic Keratosis
Actinic keratosis is identified as the most common precancerous skin lesion. Chronic sun exposure is a primary cause, presenting a serious risk of evolving into invasive squamous cell carcinoma, particularly if neglected. With millions affected each year, it is imperative to develop effective treatments, and Biofrontera is dedicated to leading this charge.
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical firm devoted to treating skin conditions, prominently focused on enhancing photodynamic therapy. The company specializes in the commercialization of Ameluz®, utilized with the RhodoLED® lamp series for efficient AK treatment. In addition, Biofrontera actively conducts clinical trials aimed at extending the use of its products for treating both non-melanoma skin cancers and moderate to severe acne.
Frequently Asked Questions
What is Ameluz® used for?
Ameluz® is utilized for photodynamic therapy to treat mild to moderate actinic keratoses on various body parts.
When is the follow-up phase expected to conclude?
The 12-month follow-up phase is anticipated to conclude in the second quarter after the active treatment phase.
What does the upcoming sNDA signify?
It indicates Biofrontera's plan to seek FDA approval to expand treatment options based on the study's results.
Who is leading the clinical study?
Dr. Nathalie Zeitouni, a clinical investigator and Mohs surgeon, is the coordinating investigator in this study.
How many patients are involved in this clinical trial?
A total of 172 patients were enrolled in the Phase 3 clinical trial for Ameluz®.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.